콘텐츠로 건너뛰기
Merck
  • Inhibition of TBK1 reduces choroidal neovascularization in vitro and in vivo.

Inhibition of TBK1 reduces choroidal neovascularization in vitro and in vivo.

Biochemical and biophysical research communications (2018-06-05)
Kaixuan Cui, Shanshan Zhang, Xiaojuan Liu, Zhenzhen Yan, Lili Huang, Xiaowei Yang, Rongrong Zhu, Aimin Sang
초록

choroidal neovascularization (CNV), a characteristic of wet age-related macular degeneration (AMD), causes severe vision loss among elderly patients. TANK-binding kinase 1 (TBK1) is a ubiquitously expressed serine-threonine kinase and is found to induce endothelial cells proliferation, represent a novel mediator of tumor angiogenesis and exert pro-inflammatory effect. However, the role of TBK1 in choroidal neovascularization has not been investigated so far. In this study, we found that the expression of TBK1 and VEGF was up-regulated in RF/6 A cells chemical hypoxia model and laser-induced mouse CNV model. Silencing of TBK1 suppressed the proliferation and tube formation activity of RF/6 A cells. Intravitreal injection of anti-TBK1 monoclonal antibody ameliorates CNV formation. Taken together, these findings exhibit a proangiogenic role for TBK1 via upregulating the expression of VEGF, and may suggest that TBK1 inhibition offers a unique and alternative method for prevention and treatment of AMD.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
MISSION® esiRNA, targeting human TBK1